Tessa Romero
Stock Analyst at JP Morgan
(1.41)
# 1543
Out of 5,329 analysts
63
Total ratings
41.86%
Success rate
22.62%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
DYN Dyne Therapeutics | Maintains: Neutral | 18 17 | 12.04 | 41.2% | 5 | Mar 21, 2025 | |
BHVN Biohaven | Maintains: Overweight | 72 68 | 22.95 | 196.3% | 6 | Mar 5, 2025 | |
UPB Upstream Bio | Initiates Coverage On: Overweight | 38 | 8.84 | 329.86% | 1 | Nov 5, 2024 | |
NMRA Neumora Therapeutics | Downgrades: Neutral | 18 15 | 0.79 | 1798.73% | 4 | Nov 5, 2024 | |
MCRB Seres Therapeutics | Downgrades: Underweight | n/a | n/a | n/a | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 31 | 32.95 | -5.92% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 71 | 37.74 | 88.13% | 4 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 29 | 7.37 | 293.49% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 31 | 17.04 | 81.92% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 46 | 30.16 | 52.52% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 25 | 14.74 | 69.61% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 4.91 | 307.33% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 8 7 | 4.41 | 58.73% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 55 | 38.73 | 42.01% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 39 36 | n/a | n/a | 4 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 140 150 | n/a | n/a | 1 | Mar 2, 2021 |